Dr. Katharine Knobil Named Agilent’s First Chief Medical Officer
March 09 2021 - 12:07PM
Business Wire
Agilent Technologies Inc. (NYSE: A), today announced that Dr.
Katharine (Kate) Knobil is joining Agilent as the company’s chief
medical officer (CMO). The chief medical officer at Agilent is a
newly created position designed to advise, lead, and elevate the
company’s presence in the health-care industry. As Agilent’s first
CMO, she will play a key role in the company’s efforts to expand
its leadership in precision medicine, supporting development of
novel therapeutics to allow clinicians to identify appropriate
patients and ultimately improve patient outcomes.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210309005866/en/
Dr. Kate Knobil, Agilent's new chief
medical officer. (Photo: Business Wire)
“Kate is an important addition to the Agilent team,” said Mike
McMullen, Agilent president and CEO. “As we see continued new
developments in patient care and as Agilent products and services
become increasingly essential to the health-care industry around
the world, Kate’s knowledge, experience and insights will be
critical for us to achieve our objectives.”
Kate Knobil has more than 20 years of experience in clinical
development and medical affairs while serving in strategic
leadership roles across the globe. She has led development and
medical affairs functions in the U.S., Europe, and in emerging
markets.
Prior to joining Agilent, Knobil served as CMO and head of
research and development at Kaleido Biosciences, where she applied
her pharmaceutical-development experience to guide the company in
its approach to translating the promise of the microbiome into
solutions for patients. Knobil’s prior experience also includes
tenure at GlaxoSmithKline, where she served in a variety of
leadership roles, including head of late-stage clinical development
in China, head of value evidence and outcomes, and CMO. During her
time with GlaxoSmithKline, she represented the company at multiple
health-regulatory agencies in several countries and led
presentations for eight U.S. Food and Drug Administration Advisory
Committee Meetings.
Knobil serves on the board of directors of Arena Pharmaceuticals
Inc. and has served on the board of directors of the National
Health Council. She received her bachelor’s degree from Cornell
University and her medical degree from the University of Texas
Southwestern Medical School. She has also completed a fellowship in
pulmonary and critical-care medicine at the Johns Hopkins
University School of Medicine.
Knobil will report directly to McMullen and will begin her role
as Agilent’s CMO in April.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in the
life-sciences, diagnostics, and applied-chemical markets,
delivering insight and innovation toward advancing the quality of
life. Agilent instruments, software, services, solutions, and
people provide trusted answers to customers' most challenging
questions. The company generated revenue of $5.34 billion in fiscal
year 2020 and employs 16,400 people worldwide. Information about
Agilent is available at www.agilent.com. To receive the latest
Agilent news, please subscribe to the Agilent Newsroom. Follow
Agilent on LinkedIn, Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210309005866/en/
Tom Beermann +1 408-553-2914 tom.beermann@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024